|
Type |
Symposium |
Area |
Recent Trends in Biopharmaceuticals Research |
Room No. |
Room 303 |
Time |
THU 16:10-16:40 |
Code |
LIFE1-2 |
Subject |
Cellular cytosol-penetrating antibody technology and its applications |
Authors |
Yong-Sung Kim Department of Applied Chemistry & Biological Engineering, Ajou University, Korea |
Abstract |
Our group recently developed a platform technology of cellular cytosol-penetrating antibody (cytotransmab), which in the IgG format can reach the cytosolic space of living cells owing to its endosomal escaping ability after receptor-mediated endocytosis. Based on the cytotransmab technology, we have engineered human IgG1 format antibody, named iMab, which specifically internalizes into the cytosol of tumor cells and then selectively binds to targeted cytosolic proteins, including oncogenic Ras mutants.
In this talk, I will present an innovative antibody technology that directly targets intracellular oncogenic KRas mutants to block the function from outside of cells after systemic administration. Our studies also demonstrate the feasibility of developing antibody therapeutics that directly target cytosolic proteins involved in disease-associated protein-protein interactions.
|
E-mail |
kimys@ajou.ac.kr |
|